Moderna’s Financial Outlook: Sell Rating Amid Challenging Vaccine Environment and Cost Reductions

In a report released on May 1, Mani Foroohar from Leerink Partners reiterated a Sell rating on Moderna (MRNA – Research Report), with a price target of $21.00.

Mani Foroohar has given his Sell rating due to a combination of factors impacting Moderna’s financial outlook. The updated model reflects a challenging environment for vaccines, particularly affecting the near-term estimates for Spikevax and mResvia. This situation is somewhat mitigated by the company’s announced cost reductions for the fiscal years 2026-2027.
Despite these cost-saving measures, the overall impact leads to a reduction in the price target from $23 to $21. These financial adjustments indicate a cautious stance on Moderna’s stock performance, prompting the Sell recommendation.

In another report released on April 24, Bank of America Securities also reiterated a Sell rating on the stock with a $26.00 price target.

MRNA’s price has also changed dramatically for the past six months – from $54.630 to $27.030, which is a -50.52% drop .